River 3 Renal Corp.
- Address
- 7550 Purple Sage
Sponsor Overview
Specializations
Inherited and Rare Kidney Diseases
River 3 Renal Corp. focuses on clinical research in Alport syndrome and primary steroid-resistant focal segmental glomerulosclerosis, with attention to renal disorders that cause progressive loss of kidney function and persistent proteinuria.
- Alport syndrome
- Primary steroid-resistant focal segmental glomerulosclerosis
- Proteinuria
The sponsor’s research activity in these conditions reflects a concentrated interest in nephrology and disease areas marked by hereditary and structural kidney pathology.
Diabetic Kidney Disease and Renal Injury
The clinical portfolio also includes diabetic kidney disease, extending the sponsor’s therapeutic interest to chronic kidney impairment associated with metabolic disease and renal damage.
- Diabetic kidney disease
- Albuminuria
- Chronic kidney impairment
This area places emphasis on kidney-related complications that are clinically relevant in both inherited and acquired renal disorders.
Renal Biomarkers and Disease Activity
Trial activity points to a strong focus on renal biomarker outcomes, particularly the reduction of proteinuria and albuminuria as indicators of kidney disease activity and treatment response.
- Proteinuria reduction
- Albuminuria reduction
- Kidney disease activity
These measures align the sponsor’s work with clinical endpoints commonly used in nephrology research.
Oral Therapeutics for Kidney Disorders
The sponsor is evaluating an orally administered renal therapy in patients with progressive kidney disease, indicating interest in oral treatment options for chronic kidney disorders.
- Oral administration
- Chronic kidney disorders
- Renal therapeutics
Current research activity spans multiple active trial sites across several countries, supporting work in multinational nephrology research.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of R3R01 for Safety, Tolerability, and Efficacy in Alport Syndrome and Primary Steroid-Resistant Focal Segmental Glomerulosclerosis |  Belgium France Germany The Netherlands | Not Recruiting |
| Evaluation of R3R01 on Albuminuria Reduction in Diabetic Kidney Disease: A Randomized, Placebo-Controlled Trial |  Denmark | Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 2 are not being studied by other sponsors.
This sponsor has worked with 9 sites across their trial portfolio.
Therapeutic Focus
- 1.Not possible to specify1 trial220 other sponsors
- 2.Nutritional and Metabolic Diseases1 trial211 other sponsors
- 3.Pathological Conditions, Signs and Symptoms1 trial91 other sponsors
Partnered Research Centres
9 centres- Address
- De Boelelaan 1117, 1081 HV Amsterdam
- Address
- Avenue De L'Hopital 1, 4000 Liège
- Address
- Hindenburgdamm 30, Lichterfelde, 12203 Berlin
- Address
- Boulevard De La Chantourne, Cs 10217, La Tronche, 38043 La Tronche
- Address
- Hippokrateslaan 10, Batiment 54, 1200 Woluwe-Saint-Lambert
- Address
- 100 Boulevard Du General Leclerc, 92110 Clichy
Want to get in touch with this sponsor?
Send a question and we'll pass it on to River 3 Renal Corp..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.